Integrative Systems Genomics and Pharmacology Define Shared Immune-Vascular Programs and Prioritize an Experimentally Testable Candidate Linking Sleep Loss to Human Atherosclerosis.

Onar LC, Yilmaz I

Open source

DOI
10.3390/biomedicines14091947
Published
2026 Aug 29
Container
Biomedicines
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/biomedicines14091947,
  title = {Integrative Systems Genomics and Pharmacology Define Shared Immune-Vascular Programs and Prioritize an Experimentally Testable Candidate Linking Sleep Loss to Human Atherosclerosis.},
  author = {Onar LC and Yilmaz I},
  year = {2026},
  journal = {Biomedicines},
  doi = {10.3390/biomedicines14091947},
  url = {https://doi.org/10.3390/biomedicines14091947}
}

RIS

TY  - JOUR
TI  - Integrative Systems Genomics and Pharmacology Define Shared Immune-Vascular Programs and Prioritize an Experimentally Testable Candidate Linking Sleep Loss to Human Atherosclerosis.
AU  - Onar LC
AU  - Yilmaz I
PY  - 2026
JO  - Biomedicines
DO  - 10.3390/biomedicines14091947
UR  - https://doi.org/10.3390/biomedicines14091947
ER  - 

APA

LC, O., & I, Y. (2026). Integrative Systems Genomics and Pharmacology Define Shared Immune-Vascular Programs and Prioritize an Experimentally Testable Candidate Linking Sleep Loss to Human Atherosclerosis.. Biomedicines. https://doi.org/10.3390/biomedicines14091947

Source records